Less than 20 % of patients with pancreatic cancer are subjected to surgical removal, whereas other patients are typically treated with chemotherapy or chemotherapy with radiation.
Pancreatic cancer is one of the few cancers in which survival has not improved substantially in 40 years.
Oridonin (ORI) can inhibit proliferation and migration in various types of cancer cell lines. We investigated the migration inhibitory effect of ORI on human pancreatic cancer SW1990 cells and dissected the possible molecular mechanism(s).CCK-8 assay was used to observe the cell viability.CHIR could attenuate the effects of ORI in SW1990 cells.We established a mice model by injecting 1 × 10 SW1990 cells into nude mice intraperitoneally to test whether ORI affects tumour metastasis.Pancreatic cancer cell lines (Aspc1, Bxpc3, Panc1, SW1990) was obtained from the American Type Culture Collection (ATCC; Manassas, VA, USA).
The cells were cultured in DMEM supplemented with 10 % FBS, 100U/ml penicillin, and 100 μg/ml streptomycin at 37 °C in a humidified atmosphere of 5 % CO cells per well).We investigated the effects of ORI on pancreatic cancer cells.ORI inhibits pancreatic cancer cell migration and EMT in vitro and in vivo by suppressing the Wnt/β-catenin signalling pathway.Numerous signalling pathways that are involved in the regulation of EMT, such as transforming growth factor-beta, notch and Wnt signalling pathways, are highly activated in metastatic pancreatic cancers and appear to be associated with prognosis .However, mechanisms underlying the antitumour activities of ORI, and whether or not it can suppress the migration of pancreatic cancer remain largely unknown.RNA extraction kit was purchased from Life Technologies Co.